Teneliximab

Monoclonal antibody
 ☒NcheckY (what is this?)  (verify)

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2] As of 2009[update], it has not entered clinical trials.[2]

References

  1. ^ International Nonproprietary Names For Pharmaceutical Substances
  2. ^ a b Law CL, Grewal IS (2009). "Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges". Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York, N.Y.: Springer Science+Business Media. pp. 8–36. doi:10.1007/978-0-387-89520-8_2. ISBN 978-0-387-89520-8. PMID 19760064.
  • v
  • t
  • e
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
  • purine synthesis inhibitors
    • Azathioprine
    • Mycophenolic acid
  • dihydroorotate dehydrogenase inhibitors
    • Leflunomide
    • Teriflunomide
  • antifolate
    • Methotrexate
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
  • v
  • t
  • e
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e